Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Geron (0IV3) Share Price & Analysis

2 Followers

0IV3 Stock Chart & Stats

$0.99$0.01(1.02%)
At close: 4:30 PM GMT
$1$1.25$1.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.97 - $1.01
52-Week Range
$0.85 - $2.00
Previous Close
$0.98
Volume
N/A
Average Volume (3M)
89.29K
Market Cap
$627.62M
Enterprise Value
$790.98M
Total Cash (Recent Filing)
$288.37M
Total Debt (Recent Filing)
$121.23M
Price to Earnings (P/E)
―
Beta
1.24
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
0
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

RYTELO Revenue Growth

Sustained RYTELO demand growth indicates expanding commercial adoption rather than reliance on a single launch milestone. Rising revenue provides a stronger base for operating leverage, supports investment in market access, and improves the durability of Geron’s commercialization strategy.

Expanding Prescriber Base

Growth in prescribing accounts broadens the commercial footprint and reduces dependence on a small group of treatment centers. Community-practice penetration can support repeat demand and create a durable distribution foundation as more physicians gain experience with RYTELO.

Low Financial Leverage

Very low debt relative to equity gives Geron greater financial flexibility while it scales RYTELO and manages development commitments. The stronger capital structure reduces interest-related pressure and leaves more capacity to fund commercial execution or selective business development.

Bears Say

Continued Cash Burn

Persistent negative operating and free cash flow means the business has not yet become self-funding despite commercial revenue growth. If this burn continues, Geron may have less flexibility for pipeline investment and could remain dependent on its cash resources or future financing.

Ongoing Net Losses

Geron’s revenue base and gross profitability have improved, but the company remains materially loss-making. Continued negative operating results can limit internally funded growth and make profitability dependent on sustained RYTELO expansion, disciplined spending, and successful operating leverage.

Myelofibrosis Trial Setback

Ending IMpactMF removes a major development opportunity in myelofibrosis and narrows the near-term upside of imetelstat beyond the RYTELO franchise. The setback also increases reliance on continued lower-risk MDS execution to support broader product and pipeline growth.

Geron News

0IV3 FAQ

What was Geron’s price range in the past 12 months?
Geron lowest share price was $0.85 and its highest was $2.00 in the past 12 months.
What is Geron’s market cap?
Geron’s market cap is $627.62M.
When is Geron’s upcoming earnings report date?
Geron’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 110 days.
How were Geron’s earnings last quarter?
Geron released its earnings results on Nov 04, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.008 by $0.008.
Is Geron overvalued?
According to Wall Street analysts Geron’s price is currently Undervalued.
Does Geron pay dividends?
Geron pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Geron dividends here
What is Geron’s EPS estimate?
Geron’s EPS estimate is 0.00.
How many shares outstanding does Geron have?
Geron has 644,238,830 shares outstanding.
What happened to Geron’s price movement after its last earnings report?
Geron reported an EPS of $0 in its last earnings report, beating expectations of -$0.008. Following the earnings report the stock price went up 10.334%.
Which hedge fund is a major shareholder of Geron?
Hedge funds hold Geron shares: the largest hedge-fund position in Geron is 1,909,136,573 shares, and hedge funds decreased their holdings by 19.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology